
CONMED (CNMD) Stock Forecast & Price Target
CONMED (CNMD) Analyst Ratings
Bulls say
Conmed Corp has demonstrated substantial growth potential through its innovative product lines, particularly with the BioBrace, which is expected to see a full market release of a new rotator cuff repair device in the latter half of 2025. The company's Foot & Ankle segment reported double-digit growth despite facing supply constraints, indicating resilience and a potential easing of these issues. Furthermore, management's conservative revenue guidance suggests a commitment to gradual revenue improvement, supported by strong performance in high-growth areas, including AirSeal and Foot & Ankle products.
Bears say
Conmed Corp has experienced a significant year-to-date decline of approximately 27%, attributed to ongoing challenges as the company undertakes a turnaround strategy. The company's current valuation is projected at 15 times the fiscal year 2025 earnings per share estimate of $4.46, reflecting a downward adjustment from a previous price target based on recent stock performance. Furthermore, capital weakness, especially on the international front, is linked to difficult year-over-year comparisons rather than an overall contraction in hospital capital budgets, indicating underlying concerns in market performance and competitive positioning.
This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.
CONMED (CNMD) Analyst Forecast & Price Prediction
Start investing in CONMED (CNMD)
Order type
Buy in
Order amount
Est. shares
0 shares